Human clinical trials of plasmid DNA vaccines.
This article gives an overview of DNA vaccines with specific emphasis on the development of DNA vaccines for clinical trials and an overview of those trials. It describes the preclinical research that demonstrated the efficacy of DNA vaccines as well as an explication of the immunologic mechanisms of action. These include the induction of cognate immune responses, such as the generation of cytolytic T lymphocytes (CTL) as well as the effect of the plasmid DNA upon the innate immune system. Specific issues related to the development of DNA as a product candidate are then discussed, including the manufacture of plasmid, the qualification of the plasmid DNA product, and the safety testing necessary for initiating clinical trials. Various human clinical trials for infectious diseases and cancer have been initiated or completed, and an overview of these trials is given. Finally, because the early clinical trials have shown less than optimal immunogenicity, methods to increase the potency of the vaccines are described.
Liu
Margaret A
MA
Transgene S.A., 11 rue de Molsheim, 67082 Strasbourg Cedex, France.
Ulmer
Jeffrey B
JB
D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D003140:Communicable Disease Control / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control*; D010957:Plasmids / Q000235:genetics* / Q000627:therapeutic use; D014611:Vaccination / Q000379:methods*; D019444:Vaccines, DNA / Q000235:genetics* / Q000627:therapeutic use*
D019444:Vaccines, DNA